

Neutrophil TLR4 expression is reduced in the airways of infants with severe bronchiolitis

C P Halfhide,¹ S P Brearey,¹ B F Flanagan,² J A Hunt,³ D Howarth,² J Cummerson,² S Edwards,⁴ C A Hart,⁵ R L Smyth¹

► Table 3 is published online only at <http://thorax.bmj.com/content/vol64/issue9>

¹ Division of Child Health, School of Reproductive and Developmental Medicine, University of Liverpool, Alder Hey Children's Hospital, Liverpool, UK; ² Division of Immunology, University of Liverpool, Liverpool, UK; ³ Division of Clinical Engineering, University of Liverpool, Liverpool, UK; ⁴ Division of Biological Sciences, University of Liverpool, Liverpool, UK; ⁵ Division of Medical Microbiology, University of Liverpool, Liverpool, UK

Correspondence to: Professor R L Smyth, Division of Child Health, Alder Hey Children's Hospital, Eaton Road, Liverpool L12 2AP, UK; r.l.smyth@liv.ac.uk

Received 10 September 2008
Accepted 20 May 2009
Published Online First
3 June 2009

ABSTRACT

Background: In respiratory syncytial virus (RSV) bronchiolitis, neutrophils account for >80% of cells recovered from the airways in bronchoalveolar lavage (BAL) fluid. This study investigated neutrophil activation and Toll-like receptor (TLR) expression in the blood and lungs of infants with severe RSV bronchiolitis.

Methods: BAL fluid and (blood) samples were collected from 24 (16) preterm and 23 (15) term infants ventilated with RSV bronchiolitis, and 12 (8) control infants. Protein levels and mRNA expression of CD11b, myeloperoxidase (MPO) and TLRs 2, 4, 7, 8 and 9 were measured in neutrophils.

Results: Blood neutrophils had more CD11b in preterm and term infants with RSV bronchiolitis than control infants ($p < 0.025$) but similar amounts of MPO. BAL fluid neutrophils from infants with RSV bronchiolitis had greater amounts of CD11b and MPO than blood neutrophils and BAL fluid neutrophils from controls ($p < 0.01$). Blood neutrophils from term infants with RSV bronchiolitis had less total TLR4 protein than preterm infants with RSV bronchiolitis ($p = 0.005$), and both had less than controls ($p < 0.04$). Total TLR4 for each group was greater in BAL fluid neutrophils than in blood neutrophils. Blood neutrophils from preterm infants with RSV bronchiolitis had greater TLR4 mRNA expression than term infants with RSV bronchiolitis ($p = 0.005$) who had similar expression to controls ($p = 0.625$).

Conclusions: In infants with severe RSV bronchiolitis, neutrophil activation starts in the blood and progresses as they are recruited into the airways. Total neutrophil TLR4 remains low in both compartments. TLR4 mRNA expression is unimpaired. This suggests that neutrophil TLR4 expression is deficient in these infants, which may explain why they develop severe RSV bronchiolitis.

Respiratory syncytial virus (RSV) bronchiolitis is the commonest cause of lower respiratory tract infection in children under the age of 1 year.¹ Symptoms begin in the upper airways and it is likely that the primary site of RSV infection is the nasal epithelium² with local spread to the lower airways.³ Initial infection of the airways leads to production of pro-inflammatory cytokines^{4,5} and chemokines⁶ which initiates the recruitment of inflammatory cells from the peripheral circulation. There is little evidence that RSV causes a viraemia,⁷ but the immunopathogenesis of RSV bronchiolitis is poorly understood. By studying cells from the blood and airways of infants with RSV bronchiolitis and comparing them with uninfected controls, information can be elucidated about the changes that inflammatory cells undergo as they are recruited to the airways.

The clinical spectrum of RSV infection is wide, from a mild upper respiratory tract infection to severe lower respiratory tract infection.¹ Risk factors for severe RSV bronchiolitis are prematurity (particularly with associated chronic lung disease),⁸ congenital heart disease⁹ and immunodeficiency.¹⁰ Half of infants ventilated for RSV bronchiolitis are born at term with no risk factors.¹¹ In previous studies we have consistently shown that term infants have a more vigorous immune response to RSV infection in their airways than preterm infants,^{4,5,12} and this may relate to the considerable maturation that occurs in the third trimester and in the first year of life.^{13,14}

Neutrophils are the predominant cell found in the inflammatory infiltrate of the bronchoalveolar lavage (BAL) fluid of infants ventilated for severe RSV bronchiolitis.⁵ They are recruited to the lungs early in the course of infection where they are known to release cytokines¹² and show delayed apoptosis.^{15,16} As the clinical condition improves, lower neutrophil concentrations are found in the BAL fluid.^{4,5} Neutrophil activation can be studied by looking at cell surface markers such as the integrins CD11b or internal markers such as myeloperoxidase (MPO) found in the neutrophil granules. Integrin expression is quickly upregulated by mobilisation of internal stores. MPO is released to the cell surface when the neutrophil is degranulating at the site of active inflammation.

Toll-like receptors (TLRs) recognise viral and bacterial pathogen-associated molecular patterns and initiate a specific inflammatory response to a range of infections.¹⁷ In RSV infection, TLRs may play an important role in regulating innate and adaptive immune responses.^{18–20} Immune responses mature with gestation and during the first few months of life when infants encounter RSV infection.²¹

Circulating neutrophils express all human TLRs except TLR3,²² but the contribution of TLRs to the pathogenesis of RSV disease is not fully understood. There has been considerable interest in the role of TLR4 in regulating RSV infection since RSV F protein has been reported to be a ligand for TLR4.²³ A clinical study found increased TLR4 expression in blood monocytes of infants with RSV bronchiolitis,²⁴ and a genetic susceptibility study identified two common TLR4 gene mutations which are associated with an increased risk of severe RSV bronchiolitis compared with mild disease (odds ratio 5.1 (95% confidence interval (CI) 1.4 to 18.1) and 4.0 (95% CI 1.3 to 12.5)).²⁵

Intracellular TLRs (3, 7, 8 and 9) recognise viral and bacterial nucleic acid in the endosomes of



This paper is freely available online under the BMJ Journals unlocked scheme, see <http://thorax.bmj.com/info/unlocked.dtl>

infected cells. RSV has been shown to interfere with TLR7 and TLR9 signalling pathways in plasmacytoid dendritic cells, resulting in significant reductions in type I interferon production.²⁰ RSV may also induce cytokine secretion and mucus production in airway epithelial cells via TLR3 signalling.²⁶

We have undertaken a large study to investigate neutrophil activation and TLR expression in the blood and BAL fluid of infants with severe RSV bronchiolitis (term and preterm) compared with control infants to delineate what changes occur in neutrophils as they migrate to the lungs from the systemic circulation.

METHODS

Study population and sample collection

Forty-seven consecutive infants aged <1 year admitted with severe RSV bronchiolitis to the intensive care unit at Royal Liverpool Children's Hospital, Alder Hey over three winter seasons were recruited to the study. RSV bronchiolitis was confirmed by direct immunofluorescence of nasopharyngeal aspirates. After informed consent, samples of peripheral blood and BAL fluid were collected as previously described.^{4 5 12} We recruited 24 participants who were born prematurely (<37 weeks gestation) and 23 who were born at term (≥ 37 weeks gestation). Data from infants born at term were analysed separately from those infants born preterm. Infants with underlying cardiorespiratory disease were excluded. The control group comprised 12 uninfected healthy infants of the same age as the infants with RSV bronchiolitis who had been ventilated prior to elective non-cardiac surgery, from whom

blood and BAL fluid samples were collected immediately after induction of anaesthesia and intubation of the airway. No recruited infant was subsequently withdrawn from the study. All samples were processed and data analysed from each recruited infant. During the first year of the study we collected BAL fluid but not blood samples.

Preparation of BAL fluid samples

Standard techniques were used to assess total and differential cell counts.^{8 9 16 27} Briefly, BAL fluid was filtered (60 μ m pore size gauze; Sefar Nitex 03-48/31, Sefar, Switzerland) to remove bulk mucus and then centrifuged. The supernatant was removed and stored at -70°C . The cellular component was resuspended in RPMI 1640 and the neutrophils purified using sedimentation gradient techniques on PolymorphPrep (Axis-Shield PoC AS, Norway). We took 59 BAL fluid samples, 47 from infants with RSV bronchiolitis (24 preterm and 23 term infants) and 12 from healthy control infants. The number of cells was highest in those infants with RSV bronchiolitis born at term and, as in previous studies,^{4 5 12} neutrophils were the predominant cell (table 1). After enrichment, >93% of the cells were neutrophils with >94% viability; the median (SD) percentages of other cells were macrophages 4 (3)%, lymphocytes 2 (1)%.

Preparation of blood neutrophils

Neutrophils were purified from whole blood by sedimentation gradient as described above. Thirty-nine blood samples were taken, 31 from infants with RSV bronchiolitis (16 preterm and

Table 1 Characteristics of patients and bronchoalveolar lavage (BAL) fluid and blood samples before enrichment

	Infants with bronchiolitis		Control infants
	Preterm	Term	
<i>Clinical information</i>			
No of patients	24	23	12
Median (range) age on admission (weeks)	3.5 (–5 to 11.7)	16 (4–56)	12 (6–20)
Weight on admission (kg)	3.3 (0.35)	5.1 (0.36)	4.3 (2.0)
Median (range) gestation at birth (weeks)	34 (27–36)	40 (39–42)	40 (37–40)
<i>BAL fluid cell counts</i>			
Total cell concentration ($\times 10^6$ cells/ml)	1.8 (0.8)	1.9 (0.5)	1.5 (0.8)
Total cell count ($\times 10^6$)	4.5 (1)	4.8 (1.2)	3 (0.5)
Percentage of viable cells	95 (2.5)	94 (2)	95 (1)
Median (range) percentage neutrophils	84 (2.5)	83 (2)	37 (3)
Median (range) percentage alveolar macrophages	12.5 (1.5)	11.6 (1.0)	47 (3)
Median (range) percentage lymphocytes	5 (0.5)	3.5 (1.0)	7 (3)
<i>Blood cell counts</i>			
No of patients	16	15	8
Total cell concentration ($\times 10^9$ cells/l)	9.95 (1.67)	9.95 (1.64)	9.44 (1.5)
Percentage of viable cells	97 (2)	96 (1)	96 (1)
Mean concentration ($\times 10^9$ /l neutrophils)	4.93 (1.46)	5.11 (1.48)	4.5 (1.56)
Mean concentration ($\times 10^9$ /l monocytes)	0.99 (0.15)	1.11 (0.17)	1.0 (0.18)
Mean concentration ($\times 10^9$ /l lymphocytes)	3.67 (0.3)	3.57 (0.44)	3.63 (0.35)
Mean concentration ($\times 10^9$ /l eosinophils)	0.088 (0.04)	0.078 (0.029)	0.082 (0.045)

Data mean (SEM) unless stated otherwise.

Table 2 Antibodies used for flow cytometry

	Antibody type	Manufacturer
Antibody raised against		
TLR2	FITC mouse monoclonal IgG _{2a}	Imgenex
TLR4	FITC mouse monoclonal IgG _{2a}	
TLR7	FITC mouse monoclonal IgG ₁	
TLR8	FITC mouse monoclonal IgG ₁	
TLR9	FITC mouse monoclonal IgG ₁	
CD16	PE mouse monoclonal IgG ₁	BD BioSciences
MPO	PE mouse monoclonal IgG ₁	DakoCytomation
CD11b	FITC mouse monoclonal IgG ₁	BD Biosciences
Isotype antibodies		
	FITC/PE mouse IgG ₁ control	Imgenex
	FITC/PE mouse IgG _{2a} control	

MPO, myeloperoxidase.

15 term) and 8 from healthy control infants. There was no difference in the total cell count between cases and control infants (table 1). After enrichment, >95% of the cells were neutrophils with >96% viability; the median (SD) percentages of other cells were monocytes 2 (1)%, lymphocytes 2 (1)%.

FACS analysis: protein expression of CD11b, MPO and TLRs 2, 4, 7, 8 and 9

All cells for FACS analysis were triple stained with ethidium monoazide bromide (EMA) (Biotium, UK) to allow exclusion of non-viable cells, a neutrophil marker (MPO or CD16) and the test antibody (TLRs 2, 4, 7, 8, 9, CD11b, MPO) or isotype control.

For cell surface expression of CD11b, TLR2 and TLR4 neutrophils were labelled and fixed (BD cytofix: 1% paraformaldehyde).

For total expression of CD11b, MPO and TLRs 2, 4, 7, 8 and 9 neutrophils were permeabilised, fixed (BD Cytofix and Cytoperm; BD Biosciences, Oxford, UK) and labelled. Samples were analysed on a FACSsort flow cytometer (Becton Dickinson) collecting a minimum of 10 000 events. Data were processed using WinMDI Version 2.8. Neutrophils were gated by size, granularity, viability and CD16 or MPO expression. TLR expression was standardised from the mean fluorescent intensity (MFI) into antigen binding capacities (ABC) relative units²⁸ to allow quantification of the antigen binding sites between different commercial antibodies, each with different binding affinities, according to the manufacturer's instructions (Simple Cellular Antigen-Bangs Laboratories, Kidlington, UK) (table 2).

Real-time polymerase chain reaction (RT-PCR)

RNA was prepared from 0.5×10^6 neutrophils using Trizol (Gibco, Basingstoke, UK), 5 µg of DNase-treated total RNA was used as a template for first strand cDNA synthesis in a 20 µl reaction using Multiscribe reverse transcriptase (Applied Biosystems, Foster City, California, USA).

The mRNA expression of TLRs 2, 4, 7, 8 and 9 was assessed using Taqman primer/probe sets (Applied Biosystems). All PCR reactions were in triplicate using an Applied Biosystems 7300 and standardised to the housekeeping gene L32 using the $\Delta\Delta C_t$ method.

Statistical analysis

Protein expression of CD11b, MPO and protein and mRNA expression of TLRs 2, 4, 7, 8 and 9 were compared from enriched neutrophil blood and BAL fluid samples in preterm and term

infants with RSV bronchiolitis and controls. Differences in means between patient groups were examined using one-way analysis of variance and independent sample *t* tests. As paired data were not available on all infants for comparison of the same neutrophils in blood and BAL fluid, pairing was ignored leading to more conservative analyses, but an analysis using only paired data is available in table 3 in the online supplement. Data were analysed using SPSS Version 15 (SPSS, Chicago, Illinois, USA). A probability level of 95% ($p < 0.05$) was considered as the threshold for statistical significance.

RESULTS

Protein expression of neutrophil activation markers in infants with RSV disease

All neutrophils in the blood and BAL fluid were positive for CD11b and MPO expression. All data presented are expressed as mean (SEM) relative ABC units ($\times 10^6$). The amounts of CD11b in blood neutrophils from both preterm and term infants with RSV bronchiolitis (0.05 (0.005) and 0.055 (0.005), respectively) were greater than in control infants (0.02 (0.005), $p < 0.025$). The amounts of CD11b in BAL fluid neutrophils in preterm and term infants with RSV bronchiolitis (0.08 (0.001) and 0.07 (0.002), respectively) were greater than in controls (0.025 (0.005), $p < 0.012$; fig 1A and B).

There was no difference between preterm and term infants with RSV bronchiolitis and controls in the amount of blood neutrophil MPO (0.15 (0.03), 0.12 (0.02) and 0.13 (0.01), respectively; $p > 0.05$). The amount of MPO was greater in BAL fluid neutrophils from both preterm and term infants with RSV bronchiolitis (0.28 (0.02) and 0.30 (0.02), respectively) than from control infants (0.14 (0.01); $p < 0.05$; fig 1C). There were no significant differences in the expression of CD11b or MPO between preterm and term infants in blood or BAL fluid neutrophils. For both groups of infants with severe RSV bronchiolitis, there were greater amounts of CD11b and MPO in neutrophils from the BAL fluid than from the blood. There was no difference between these compartments for either marker in control infants.

Expression of TLRs in infants with RSV bronchiolitis and controls

All neutrophils in the blood and BAL fluid were positive for expression of TLRs 2, 4, 7, 8 and 9. There was no difference between cell surface TLR2 expression on neutrophils from blood or BAL fluid or between preterm, term or control infants (fig 2A, B), nor was there any difference between groups or compartments for total TLR2 (fig 2A, C). There was no difference in neutrophil cell surface TLR4 expression between the three groups in either the blood or the BAL fluid (fig 3A, B). However, in blood neutrophils the total TLR4 for term infants with RSV bronchiolitis was significantly less than for preterm infants with RSV bronchiolitis (0.51 (0.023) vs 0.70 (0.038), $p = 0.036$), and both were less than for control infants (1.0 (0.035), $p = 0.005$; fig 3B).

In the BAL fluid, total neutrophil TLR4 was significantly less in term infants with RSV bronchiolitis than in preterm infants with RSV bronchiolitis (0.70 (0.02) vs 0.92 (0.02), $p = 0.03$), and both were less than in control infants (1.70 (0.028), $p = 0.001$; fig 3A, C). For each patient group there was significantly more total neutrophil TLR4 expressed in the BAL fluid than in the blood ($p < 0.05$).

For the TLRs expressed intracellularly (TLRs 7, 8 and 9) there was considerably less overall expression in neutrophils from blood and BAL fluid than those expressed on the cell surface

Figure 1 Protein expression of neutrophil activation markers is upregulated in respiratory syncytial virus (RSV) disease. Data are presented as mean (SEM) arbitrary units of antigen binding capacity (ABC) $\times 10^6$.

(A) Histograms of flow cytometry data from two representative patients, an infant with RSV bronchiolitis (left) and a control infant (right), showing the mean protein expression of CD11b in the bronchoalveolar lavage (BAL) fluid compared with isotype control (shaded). (B) To determine mean cell surface CD11b expression, blood and airway neutrophils were stained, fixed and analysed by flow cytometry. CD11b expression was similar for term ($n = 15$) and preterm infants ($n = 16$) with RSV bronchiolitis, and both were significantly greater than controls ($n = 8$). There was significantly greater cell surface CD11b protein expression in the BAL neutrophils than in the blood neutrophils. (C) To determine mean total myeloperoxidase (MPO) expression, neutrophils from blood and BAL fluid were fixed and permeabilised before staining and analysed by flow cytometry. For blood neutrophils there was no difference in protein expression of MPO between infants with bronchiolitis ($n = 31$) and controls ($n = 8$). For the BAL fluid neutrophils, both term ($n = 15$) and preterm infants ($n = 16$) with RSV bronchiolitis had significantly more MPO expression than control infants ($n = 8$). There was significantly more MPO in BAL fluid than in blood. * $p < 0.05$.





Figure 2 Toll-like receptor (TLR) 2 protein expression is unaltered in infants with severe respiratory syncytial virus (RSV) bronchiolitis. All data presented as mean (SEM) arbitrary units of antigen binding capacity (ABC) $\times 10^6$. (A) Representative histograms from flow cytometric staining of TLR2 on bronchoalveolar lavage (BAL) fluid neutrophils from three infants, a preterm infant with RSV bronchiolitis, a term infant with RSV bronchiolitis and a control infant. (B) The mean expression of cell surface TLR2 was determined by staining and fixing neutrophils prior to analysis by flow cytometry. The mean expression of cell surface TLR2 was similar between all three patient groups for airway and blood neutrophils (preterm infants, $n = 16$; term infants, $n = 15$; controls, $n = 8$) and for each group between blood and BAL fluid neutrophils. (C) To determine total TLR2, the neutrophils were fixed and permeabilised prior to analysis by flow cytometry. Total neutrophil TLR2 was similar between all three patient groups in both blood and BAL fluid (preterm RSV, $n = 16$; term RSV, $n = 15$; control, $n = 8$) and between blood and BAL fluid for each group.




Figure 3 Toll-like receptor (TLR) 4 protein expression is downregulated in infants with severe respiratory syncytial virus (RSV) bronchiolitis. Data presented as mean (SEM) arbitrary units of antigen binding capacity (ABC) $\times 10^6$. (A) Representative histograms from flow cytometric staining of TLR4 on bronchoalveolar lavage (BAL) fluid neutrophils from three infants, a preterm and a term infant with RSV bronchiolitis and a control infant. TLR4 expression was greater than TLR2. For TLR4, term infants with bronchiolitis had less total TLR4 than preterm infants with bronchiolitis and control infants. Shaded histograms are isotype controls. (B) Expression of cell surface TLR4 was analysed by flow cytometry after staining and fixing neutrophils. There was no significant difference between patient groups for cell surface expression of neutrophil TLR4 for either BAL fluid neutrophils (preterm RSV, $n = 24$; term RSV, $n = 23$; controls, $n = 12$) or blood neutrophils (preterm RSV, $n = 16$; term RSV, $n = 15$; controls, $n = 8$) or between blood and BAL fluid neutrophils for each patient group. (C) To determine total neutrophil TLR4 expression, cells were fixed and permeabilised before analysis by flow cytometry. In both blood and BAL fluid neutrophils, term and preterm infants with RSV bronchiolitis had significantly less TLR4 expression than control infants. Term infants with RSV bronchiolitis had significantly less total TLR4 than preterm infants with bronchiolitis ($p = 0.03$). * $p < 0.05$. Total neutrophil TLR4 in BAL fluid was significantly greater ($p < 0.05$) than in blood for all three groups (not shown).

(TLRs 2 and 4). The total ABC range for TLRs 7, 8 and 9 was 982–9070 compared with the much higher range of total TLR2 and TLR4 of $0.138\text{--}1.7 \times 10^6$. There were no significant differences in neutrophil expression of the intracellular TLRs 7, 8 and 9 between term and preterm infants with bronchiolitis and controls in either blood or BAL fluid neutrophils or between BAL fluid and blood within each group (data not shown).

Neutrophil expression of TLR mRNA in infants with severe RSV bronchiolitis compared with healthy infants

In the blood, neutrophil mRNA expression for TLR4 was similar for term infants with RSV bronchiolitis and control infants (34.84 (2.168) and 48.16 (2.758), respectively, $p = 0.625$; data expressed as mean (SEM) logfold ratio of TLR mRNA to L32 mRNA). Blood neutrophil TLR4 mRNA expression of preterm infants with RSV bronchiolitis (566.27 (19.825)) was much greater than that of term infants with RSV bronchiolitis ($p = 0.005$) or controls ($p = 0.021$; fig 4A).

In the BAL fluid, neutrophil TLR4 mRNA expression was significantly less than in the blood for each patient group. Similarly, BAL fluid neutrophil mRNA expression for TLR4 was greater for preterm infants with RSV bronchiolitis (4.38 (0.122)) than for term infants with RSV bronchiolitis (2.46 (0.129), $p = 0.037$) and for controls (1.12 (0.577), $p = 0.034$). As in the blood, BAL fluid neutrophil TLR4 mRNA expression for term infants with RSV bronchiolitis was similar to that of controls ($p = 0.6$, fig 4B).

To determine if the increased expression of TLR4 mRNA in the blood compared with the BAL fluid was also observed for the other TLRs, the mean mRNA expression of TLRs 2, 7, 8 and 9 in blood neutrophils for the two groups with RSV bronchiolitis and the control group was measured (fig 4C). For TLR7 and 9 there was a similar pattern of greatly increased neutrophil mRNA expression in preterm infants with RSV

bronchiolitis compared with the other two groups. Neutrophil TLR7 mRNA was undetectable in controls. There were only low and similar levels of expression of neutrophil TLR2 in the three groups and of TLR8 mRNA in term infants with RSV bronchiolitis and controls ($p > 0.05$). There was no detectable expression of neutrophil TLR8 mRNA in preterm infants with RSV bronchiolitis. In the BAL fluid there was very little neutrophil mRNA expression of TLRs 2, 7, 8 and 9 compared with blood (data not shown).

DISCUSSION

This study has shown for the first time that neutrophils from infants with severe RSV bronchiolitis are activated both in the peripheral circulation and, to a greater degree, in the lower airways. This was associated with reduced neutrophil TLR4 in both compartments, with the lowest amounts for term infants with RSV bronchiolitis. The expression of neutrophil TLRs 2, 7, 8 and 9 in both blood and BAL fluid was similar in all three groups. This finding of reduced TLR4 protein expression raises the possibility of an impaired innate immune response and contrasts with findings of many clinical studies which have shown highly overexuberant inflammatory responses during RSV bronchiolitis. This is the first study to investigate the role of TLRs in both the airway and circulation of infants with RSV bronchiolitis. We studied the expression of the human TLRs currently believed to be involved in viral recognition in a group of infants with the most severe manifestations of RSV disease and no known risk factors. We analysed infant neutrophils, the biology and immune function of which is very different from neutrophils of adults.²⁹

This work has some limitations. First, as only infants with severe disease were intubated, we were unable to collect BAL fluid samples from infants with mild or moderate disease to determine whether these changes were more marked with




Figure 4 Neutrophil TLR4 mRNA expression predominantly occurs in the blood compared with the bronchoalveolar lavage (BAL) fluid and is similar in term and control infants. Data presented as mean (SEM) logfold ratio after expression of mRNA assessed by RT-PCR for all Toll-like receptors (TLRs) standardised as a ratio to mRNA for the housekeeping gene L32. (A) Neutrophil TLR4 mRNA was significantly increased in blood neutrophils, mRNA expression was greater in preterm infants ($n = 16$) than in term infants with respiratory syncytial virus (RSV) bronchiolitis ($n = 15$), but there was no significant difference between term infants with RSV bronchiolitis and controls ($n = 8$). (B) Neutrophil TLR4 mRNA was significantly increased in BAL fluid neutrophils from preterm infants with RSV bronchiolitis ($n = 16$) compared with term infants with RSV bronchiolitis ($n = 15$), which was similar to control infants ($n = 8$). There was considerably less mRNA TLR4 for each patient group in the BAL fluid than in the blood (not shown). (C) As the blood seemed to be the main site of TLR4 mRNA production, neutrophil mRNA expression of TLR 2, 7, 8 and 9 was determined for blood neutrophils for preterm ($n = 16$) and term infants with RSV bronchiolitis ($n = 15$) and for controls ($n = 8$). There was no significant difference in the expression of blood neutrophil mRNA TLR2 between the three patient groups. Preterm infants had significantly greater expression of TLR7 and 9 in blood neutrophils than term or control infants ($p < 0.05$). The low levels of expression of neutrophil TLR8 in term infants with RSV bronchiolitis were similar to the levels in control infants; levels of TLR8 in preterm infants with RSV bronchiolitis were undetectable. * $p < 0.05$.

increasing disease severity as suggested by genetic susceptibility studies.²⁵ Second, although our findings may suggest a constitutive reduction in neutrophil TLR4 expression in some infants, we do not know whether expression was altered before the onset of RSV disease or after recovery. RSV F protein has been shown to bind to TLR4 on monocytes,³⁰ and we have some preliminary data which suggest that the RSV virus may bind to, or associate with, neutrophils in the BAL fluid of RSV-infected infants. Whether this results from an interaction between RSV and a specific receptor such as TLR4 has not been determined. We have undertaken some preliminary *in vitro* work with neutrophils from healthy adults which shows no evidence of interference by RSV with TLR4 antibody binding or TLR4 detection in our assay. Additional evidence to suggest that RSV F protein binding is not interfering with TLR4 detection is provided by the observation that TLR4 expression on the

surface of neutrophils was similar between our three groups and between the blood and the BAL fluid within the groups, whereas there are differences for these comparisons in total TLR4 expression.

As the neutrophils from the peripheral circulation of infants with severe RSV bronchiolitis expressed higher levels of CD11b than uninfected controls, although recirculation from the lung cannot be excluded, it appears that they become partially activated or primed in the peripheral circulation before recruitment into the lung. In the lung, neutrophils express higher levels of total and cell surface CD11b and MPO, which suggests either progressive activation^{31–33} and release of intracellular MPO by degranulation at this site or, alternatively, the selective recruitment of highly activated neutrophils from the peripheral circulation.

The observed decrease in neutrophil intracellular TLR4 protein expression could be due to reduced synthesis, mobilisa-

tion to the cell surface or increased degradation. The first two of these seem unlikely as, compared with controls, neutrophil TLR4 mRNA expression was greatly increased in preterm and similar in term infants and TLR4 expression on the surface of neutrophils was similar between the three groups. A precedent for TLR4 degradation comes from epithelial cells where TLR4/MD2 complexes are degraded once engaged by an agonist.³⁴ The third explanation alone seems unlikely as neutrophil TLR4 was not only reduced in BAL fluid neutrophils—where RSV is present in large titres—but also on blood neutrophils. There is currently no evidence to suggest that RSV causes a viraemia.⁷

As only the expression of TLR4 and not of other TLRs is markedly reduced in the main infiltrating inflammatory cell during active infection, this suggests both a specific effect on TLR4 expression and that neutrophils and TLR4 play an important role in host defence against RSV infection. TLR4 signalling has primarily been studied in airway epithelial cells during RSV infection. There is very little work on RSV infection and TLR pathways in blood-derived cells and none, to our knowledge, in clinical studies that investigated neutrophils. Deficiencies in TLR pathways have been shown to be important in other viral infections and modulate host defence—for example, the *Vaccinia* virus protein A46R blocks TLR4 signalling³⁵ in human epithelial tumour cell lines (HeLa cells) and *Vaccinia* virus lacking A46R has attenuated virulence.

One of the striking findings of our study was that, in neutrophils of preterm infants with RSV bronchiolitis compared with controls, despite reduced protein expression of neutrophil TLR4 in the blood and BAL fluid, there were vastly increased levels of TLR4 mRNA in the blood. In preterm infants this may represent immaturity of the TLR4 transcription pathway. However, in previous unpublished studies we have measured mRNA for TLRs 2, 4, 7 and 9 in two groups of controls (those born at term and those born preterm) and found no differences in expression between the groups. In the preterm infants this may represent an appropriate response to RSV infection with increased degradation and utilisation of TLR4-dependent pathways to help clear the infection, or these findings may reflect the immunological immaturity of these infants. As the expression of TLRs has been shown to increase with gestational age,²¹ the finding that total neutrophil TLR4 is much less in term infants than in preterm infants with severe RSV disease may suggest that term infants with severe disease have a constitutive abnormality in TLR4 expression. This may be related to the genetic polymorphisms in TLR4 that are associated with an increased risk of severe disease^{24, 25} and with impaired TLR4 signalling in response to RSV F protein.²⁷

This study has highlighted important aspects about the role of neutrophils in RSV disease and the differences in the immunopathogenesis in preterm and term infants. In vitro studies are needed to determine whether the abnormalities in TLR4 expression contribute to or are a result of RSV disease. TLR4 agonists are currently undergoing phase II clinical trials, so elucidating these mechanisms further will have important therapeutic implications for infants with severe RSV bronchiolitis.

Acknowledgements: The authors thank all the staff of the Paediatric Intensive Care Unit of Alder Hey Children's Hospital, especially the physiotherapists Paul Ritson and Vanessa Compton, for help during the collection of the BAL samples; Paul McNamara and Calum Semple for their earlier assistance and ideas; and Angela Booth and Graham Jeffers for their help in processing the samples.

Funding: British Lung Foundation, Action Medical Research and the Miss Jean Coubrough Charitable Trust.

Competing interests: None.

Ethics approval: The local paediatric research ethics committee (Royal Liverpool Children's Hospital) approved the study and informed consent was obtained from the parents.

CPH and SPB contributed equally to this work.

Provenance and peer review: Not commissioned; externally peer reviewed.

REFERENCES

1. Smyth RL, Openshaw PJ. Bronchiolitis. *Lancet* 2006;**368**:312–22.
2. Hall CB, Douglas RG Jr, Geiman JM. Quantitative shedding patterns of respiratory syncytial virus in infants. *J Infect Dis* 1975;**132**:151–6.
3. Hall CB, Douglas RG Jr, Geiman JM. Respiratory syncytial virus infections in infants: quantitation and duration of shedding. *J Pediatr* 1976;**89**:11–5.
4. McNamara PS, Flanagan BF, Selby AM, et al. Pro- and anti-inflammatory responses in respiratory syncytial virus bronchiolitis. *Eur Respir J* 2004;**23**:106–12.
5. McNamara PS, Ritson P, Selby A, et al. Bronchoalveolar lavage cellularity in infants with severe respiratory syncytial virus bronchiolitis. *Arch Dis Child* 2003;**88**:922–6.
6. McNamara PS, Flanagan BF, Hart CA, et al. Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. *J Infect Dis* 2005;**191**:1225–32.
7. O'Donnell DR, McGarvey MJ, Tully JM, et al. Respiratory syncytial virus RNA in cells from the peripheral blood during acute infection. *J Pediatr* 1998;**133**:272–4.
8. Carbonell-Estrany X, Quero J. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. *Pediatr Infect Dis J* 2001;**20**:874–9.
9. Moler FW, Khan AS, Meliones JN, et al. Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. *Crit Care Med* 1992;**20**:1406–13.
10. Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial viral infection in children with compromised immune function. *N Engl J Med* 1986;**315**:77–81.
11. Shay DK, Holman RC, Roosevelt GE, et al. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979–1997. *J Infect Dis* 2001;**183**:16–22.
12. McNamara PS, Flanagan BF, Baldwin LM, et al. Interleukin 9 production in the lungs of infants with severe respiratory syncytial virus bronchiolitis. *Lancet* 2004;**363**:1031–7.
13. Forster-Waldl E, Sadeghi K, Tamandl D, et al. Monocyte toll-like receptor 4 expression and LPS-induced cytokine production increase during gestational aging. *Pediatr Res* 2005;**58**:121–4.
14. Levy O, Zarembek KA, Roy RM, et al. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. *J Immunol* 2004;**173**:4627–34.
15. Jones A, Qui JM, Bataki E, et al. Neutrophil survival is prolonged in the airways of healthy infants and infants with RSV bronchiolitis. *Eur Respir J* 2002;**20**:651–7.
16. Lindemans CA, Coffey PJ, Schellens IM, et al. Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-kappaB-dependent mechanism. *J Immunol* 2006;**176**:5529–37.
17. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. *Cell* 2006;**124**:783–801.
18. Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. *Nat Immunol* 2000;**1**:398–401.
19. Rudd BD, Smit JJ, Flavell RA, et al. Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. *J Immunol* 2006;**176**:1937–42.
20. Schlender J, Hornung V, Finke S, et al. Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. *J Virol* 2005;**79**:5507–15.
21. Angelone DF, Wessels MR, Coughlin M, et al. Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-alpha production in vitro and in vivo. *Pediatr Res* 2006;**60**:205–9.
22. Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. *Blood* 2003;**102**:2660–9.
23. Haynes LM, Moore DD, Kurt-Jones EA, et al. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. *J Virol* 2001;**75**:10730–7.
24. Gagro A, Tominac M, Krsulovic-Hresic V, et al. Increased Toll-like receptor 4 expression in infants with respiratory syncytial virus bronchiolitis. *Clin Exp Immunol* 2004;**135**:267–72.
25. Tal G, Mandelberg A, Dalal I, et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. *J Infect Dis* 2004;**189**:2057–63.
26. Groskreutz DJ, Monick MM, Powers LS, et al. Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. *J Immunol* 2006;**176**:1733–40.
27. Mandelberg A, Tal G, Naugolny L, et al. Lipopolysaccharide hyporesponsiveness as a risk factor for intensive care unit hospitalization in infants with respiratory syncytial virus bronchiolitis. *Clin Exp Immunol* 2006;**144**:48–52.
28. Schwartz A, Fernandez-Repollat E. Development of clinical standards for flow cytometry. *Ann N Y Acad Sci* 1993;**677**:28–39.
29. Molloy EJ, O'Neill AJ, Doyle BT, et al. Effects of heat shock and hypoxia on neonatal neutrophil lipopolysaccharide responses: altered apoptosis, Toll-like receptor-4 and CD11b expression compared with adults. *Biol Neonate* 2006;**90**:34–9.

30. **Haeberle HA**, Takizawa R, Casola A, *et al*. Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways. *J Infect Dis* 2002;**186**:1199–206.
31. **Bataki EL**, Evans GS, Everard ML. Respiratory syncytial virus and neutrophil activation. *Clin Exp Immunol* 2005;**140**:470–7.
32. **Jaovisidha P**, Peeples ME, Brees AA, *et al*. Respiratory syncytial virus stimulates neutrophil degranulation and chemokine release. *J Immunol* 1999;**163**:2816–20.
33. **Sabroe I**, Dower SK, Whyte MK. The role of Toll-like receptors in the regulation of neutrophil migration, activation, and apoptosis. *Clin Infect Dis* 2005;**41**(Suppl 7):S421–6.
34. **Lauer S**, Kunde YA, Apodaca TA, *et al*. Soluble MD2 increases TLR4 levels on the epithelial cell surface. *Cell Immunol* 2009;**255**:8–16.
35. **Bowie A**, Kiss-Toth E, Symons JA, *et al*. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. *Proc Natl Acad Sci USA* 2000;**97**:10162–7.

Lung alert

Influenza infection: the origin and role of IL10

With fears of an influenza pandemic looming, understanding the mechanism by which pathogenic strains of influenza cause lethal lung injury could not be more relevant. Interleukin 10 (IL10) is an anti-inflammatory cytokine recognised to prevent excessive injury in bacterial and parasitic infections. This series of elegant experiments focuses on the role of IL10 in influenza-infected mice, the proportion of IL10 produced by effector T cell (Teff) subtypes and the kinetics of this response.

The authors demonstrate that CD8+ Teff cells are the main contributor of IL10 in influenza-infected lungs, with IL10-producing CD8+ Teff cells outnumbering IL10-producing CD4+ Teff cells twofold. They propose that the time at which IL10-producing T cells are found (days 6–26 after infection) corresponds to our understanding of CD8+ migration kinetics, providing further evidence that CD8+ Teff cells are the main source of IL10. Similarly, using knock-out mice, the authors showed that T cell depletion correlates with a significant reduction in IL10 production. Bronchoalveolar lavage fluid from infected wild-type mice produced nearly 6000 pg/ml IL10 while production in infected T cell-deficient mice approached zero.

An interesting final experiment examined the effect of IL10 receptor (IL10R) blockage on survival rate. Twelve mice were treated with IL10R-specific monoclonal antibodies. A dramatically higher proportion of these mice died once infected with influenza and this was partially reversible with corticosteroid administration.

This paper provides novel evidence of the significance of IL10 in viral infections, specifically that Teff cells are crucial in regulating excess injury in influenza infection via production of IL10. The authors speculate that highly pathogenic influenza strains may selectively suppress IL10 production by Teff cells. This will be important in guiding future studies in humans.

- Sun J, Madan R, Karp CL, *et al*. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. *Nat Med* 2009;**15**:277–84.

L Cunningham

Correspondence to: L Cunningham, Core Medical Trainee, Royal Free Hospital, London, UK; cunninghamleila@yahoo.co.uk